Literature DB >> 19129380

Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment.

Cai Song1, Xiang Yang Zhang, Mehar Manku.   

Abstract

An increased inflammatory response and deficient synthesis of neurotrophic factors (NTFs) may contribute to the etiology of depression. However, the interrelationship between inflammation and NTFs is unknown. Recently, ethyl-eicosapentaenoate (EPA) has been used to treat depression. The mechanism by which EPA benefits depression is also unclear. Using the olfactory bulbectomized (OB) rat model of depression, this study evaluated two pathways from bulbectomy to the induction of depression-like changes (the inflammation-hypothalamic-pituitary-adrenal axis-stress response pathway and inflammation-nerve growth factor-memory pathway) and the effect of EPA on these pathways. When compared with sham-operated rats fed a control diet, significantly increased locomotor and rearing activities in an "open field," impaired memory in the Morris water maze, increased expression of corticotrophin-releasing factor (CRF), and increased secretion of corticosterone were found in OB rats. mRNA expression of nerve growth factor (NGF) was significantly lower in the hippocampus, and phospholipase A2 (PLA2) was higher in the hypothalamus; this change was associated with increased interleukin-1beta (IL-1beta) and prostaglandin E2 (PGE2) in the serum and brain. EPA treatments normalized these behavioral impairments and reduced CRF expression and corticosterone secretion. EPA also reduced serum concentrations of IL-1beta and PGE2, but reversed NGF reduction. Similar to the effects of EPA, the anti-inflammatory drug celecoxib significantly reduced blood PGE2, IL-1beta, and corticosterone concentrations and increased NGF expression in OB rats. Furthermore, anti-NGF treatment blocked EPA effects on behavior. These results suggest that an interaction exists between inflammation and NGF in the depression model. EPA may improve depression via its anti-inflammation properties and the upregulation of NGF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129380      PMCID: PMC6664916          DOI: 10.1523/JNEUROSCI.3569-08.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  36 in total

1.  Activation of Glycogen Synthase Kinase-3 Mediates the Olfactory Deficit-Induced Hippocampal Impairments.

Authors:  Juan Hu; He-Zhou Huang; Xiang Wang; Ao-Ji Xie; Xiong Wang; Dan Liu; Jian-Zhi Wang; Ling-Qiang Zhu
Journal:  Mol Neurobiol       Date:  2014-11-05       Impact factor: 5.590

Review 2.  Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research.

Authors:  Michael Maes; Gabriel Nowak; Javier R Caso; Juan Carlos Leza; Cai Song; Marta Kubera; Hans Klein; Piotr Galecki; Cristiano Noto; Enrico Glaab; Rudi Balling; Michael Berk
Journal:  Mol Neurobiol       Date:  2015-05-02       Impact factor: 5.590

Review 3.  Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.

Authors:  Jennifer M Loftis; Marilyn Huckans; Benjamin J Morasco
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

4.  Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Authors:  Patricia Munoz-Garrido; José J G Marin; María J Perugorria; Aura D Urribarri; Oihane Erice; Elena Sáez; Miriam Úriz; Sarai Sarvide; Ainhoa Portu; Axel R Concepcion; Marta R Romero; María J Monte; Álvaro Santos-Laso; Elizabeth Hijona; Raúl Jimenez-Agüero; Marco Marzioni; Ulrich Beuers; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Joost P H Drenth; Jesús M Banales
Journal:  J Hepatol       Date:  2015-06-01       Impact factor: 25.083

Review 5.  Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?

Authors:  Robert K McNamara; Francis E Lotrich
Journal:  Expert Rev Neurother       Date:  2012-09       Impact factor: 4.618

6.  Intranasal administration of nerve growth factor produces antidepressant-like effects in animals.

Authors:  Cui-ge Shi; Lu-ming Wang; Ying Wu; Peng Wang; Zhu-jun Gan; Kai Lin; Li-xin Jiang; Zhi-qing Xu; Ming Fan
Journal:  Neurochem Res       Date:  2010-06-03       Impact factor: 3.996

7.  Etazolate, a phosphodiesterase-4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy.

Authors:  Ankur Jindal; Radhakrishnan Mahesh; Shvetank Bhatt
Journal:  Psychopharmacology (Berl)       Date:  2014-08-15       Impact factor: 4.530

8.  The impact of chronic stress on the rat brain lipidome.

Authors:  T G Oliveira; R B Chan; F V Bravo; A Miranda; R R Silva; B Zhou; F Marques; V Pinto; J J Cerqueira; G Di Paolo; N Sousa
Journal:  Mol Psychiatry       Date:  2015-03-10       Impact factor: 15.992

9.  Anti-Oxidative Effects of Melatonin Receptor Agonist and Omega-3 Polyunsaturated Fatty Acids in Neuronal SH-SY5Y Cells: Deciphering Synergic Effects on Anti-Depressant Mechanisms.

Authors:  Senthil Kumaran Satyanarayanan; Yin-Hwa Shih; Yu-Chuan Chien; Shih-Yi Huang; Piotr Gałecki; Siegfried Kasper; Jane Pei-Chen Chang; Kuan-Pin Su
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

10.  Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease.

Authors:  Zhongmei Chen; Yunpeng Yang; Xu Yang; Changqing Zhou; Fengqun Li; Peng Lei; Ling Zhong; Xin Jin; Guoguang Peng
Journal:  Neurol Sci       Date:  2013-01-25       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.